Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056565663> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2056565663 endingPage "A659" @default.
- W2056565663 startingPage "A659" @default.
- W2056565663 abstract "The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable patients to access therapies that are not routinely available on the National Health Service (NHS). In April 2013, NHS England became responsible for the management of the CDF with a single national list of drugs for prioritised funding. As the CDF has recently been extended to 2016, it is increasingly important to understand the key criteria for inclusion on the CDF-approved list, which this research aims to define. CDF appraisal reports were sourced from the NHS England website (April 2013 – March 2014) and the date, decision, and key rationale were extracted. 56 CDF decision summaries were available, 14 (25%) received full approval, 10 (18%) received conditional/restricted approval, 28 (50%) were rejected, and 4 (7%) were referred to commissioning. The key clinical attributes of each oncologic were given a numerical scoring that sum to a possible maximum +21 and minimum -4. The maximum score of any drug appraised was +8 and the minimum was -1. Excluding appraisals referred to commissioning, 16/18 appraisals scoring <2 were rejected (89%) compared to only 5/25 (20%) scoring >=2 (4/5 primarily due to trial comparator choice). 9 were not scored due to a lack of appropriate evidence. 11 submissions were only based on Phase II data (for such submissions, efficacy scores were halved), 5 of which were approved. A score of >=2 seems to be the key clinical threshold above which most drugs are CDF-approved, below which most are rejected. Given that 43/47 scoring drugs scored -1 for toxicity, this means that 3 points are typically required, which can come through a 4-5 month Progression Free Survival or Overall Survival gain (or a 2-3 month gain in both), but this must be versus the clinically relevant comparator." @default.
- W2056565663 created "2016-06-24" @default.
- W2056565663 creator A5024624616 @default.
- W2056565663 date "2014-11-01" @default.
- W2056565663 modified "2023-09-30" @default.
- W2056565663 title "The Cancer Drugs Fund: A Systematic Analysis of the Requirements For Inclusion on the English National List of Drugs for Priority Funding" @default.
- W2056565663 doi "https://doi.org/10.1016/j.jval.2014.08.2410" @default.
- W2056565663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27202394" @default.
- W2056565663 hasPublicationYear "2014" @default.
- W2056565663 type Work @default.
- W2056565663 sameAs 2056565663 @default.
- W2056565663 citedByCount "0" @default.
- W2056565663 crossrefType "journal-article" @default.
- W2056565663 hasAuthorship W2056565663A5024624616 @default.
- W2056565663 hasBestOaLocation W20565656631 @default.
- W2056565663 hasConcept C109359841 @default.
- W2056565663 hasConcept C121608353 @default.
- W2056565663 hasConcept C126322002 @default.
- W2056565663 hasConcept C127413603 @default.
- W2056565663 hasConcept C144133560 @default.
- W2056565663 hasConcept C151719136 @default.
- W2056565663 hasConcept C15744967 @default.
- W2056565663 hasConcept C162118730 @default.
- W2056565663 hasConcept C17744445 @default.
- W2056565663 hasConcept C199539241 @default.
- W2056565663 hasConcept C3020340455 @default.
- W2056565663 hasConcept C42475967 @default.
- W2056565663 hasConcept C512399662 @default.
- W2056565663 hasConcept C535046627 @default.
- W2056565663 hasConcept C71924100 @default.
- W2056565663 hasConcept C77805123 @default.
- W2056565663 hasConceptScore W2056565663C109359841 @default.
- W2056565663 hasConceptScore W2056565663C121608353 @default.
- W2056565663 hasConceptScore W2056565663C126322002 @default.
- W2056565663 hasConceptScore W2056565663C127413603 @default.
- W2056565663 hasConceptScore W2056565663C144133560 @default.
- W2056565663 hasConceptScore W2056565663C151719136 @default.
- W2056565663 hasConceptScore W2056565663C15744967 @default.
- W2056565663 hasConceptScore W2056565663C162118730 @default.
- W2056565663 hasConceptScore W2056565663C17744445 @default.
- W2056565663 hasConceptScore W2056565663C199539241 @default.
- W2056565663 hasConceptScore W2056565663C3020340455 @default.
- W2056565663 hasConceptScore W2056565663C42475967 @default.
- W2056565663 hasConceptScore W2056565663C512399662 @default.
- W2056565663 hasConceptScore W2056565663C535046627 @default.
- W2056565663 hasConceptScore W2056565663C71924100 @default.
- W2056565663 hasConceptScore W2056565663C77805123 @default.
- W2056565663 hasIssue "7" @default.
- W2056565663 hasLocation W20565656631 @default.
- W2056565663 hasLocation W20565656632 @default.
- W2056565663 hasOpenAccess W2056565663 @default.
- W2056565663 hasPrimaryLocation W20565656631 @default.
- W2056565663 hasRelatedWork W1530319254 @default.
- W2056565663 hasRelatedWork W1890692262 @default.
- W2056565663 hasRelatedWork W2028649356 @default.
- W2056565663 hasRelatedWork W2065711403 @default.
- W2056565663 hasRelatedWork W2294850333 @default.
- W2056565663 hasRelatedWork W2337969177 @default.
- W2056565663 hasRelatedWork W2581363095 @default.
- W2056565663 hasRelatedWork W2768515060 @default.
- W2056565663 hasRelatedWork W2957285118 @default.
- W2056565663 hasRelatedWork W4289549996 @default.
- W2056565663 hasVolume "17" @default.
- W2056565663 isParatext "false" @default.
- W2056565663 isRetracted "false" @default.
- W2056565663 magId "2056565663" @default.
- W2056565663 workType "article" @default.